|
Market Closed -
Nasdaq
16:00:00 2026-09-04 EDT
|
5-day change | 1st Jan Change | ||
| 7.820 USD | -0.26% |
|
+28.41% | -44.89% |
| 09-03 | NextCure Enters Into Ninth Amendment To Lease Agreement And Vacates Premises At 8000 Virginia Manor Road | CI |
| 08-12 | RTW Biotech's Avere to go public in US in reverse merger with NextCure | AN |
Company Valuation: NextCure, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 165.8 | 39.16 | 31.81 | 21.59 | 49.74 | 35.79 | - | - |
| Change | - | -76.37% | -18.77% | -32.12% | 130.37% | -28.04% | - | - |
| Enterprise Value (EV) | 165.8 | 39.16 | 31.81 | 21.59 | 49.74 | 35.79 | 35.79 | 35.79 |
| Change | - | -76.37% | -18.77% | -32.12% | 130.37% | -28.04% | 0% | 0% |
| P/E | -2.39x | -0.52x | -0.51x | -0.39x | -0.72x | -1.23x | -1.33x | -6.41x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0.07x | 0x | 0x | 0x | 0x | 0.19x | 0.1x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 5.77x |
| EV / Revenue | - | - | - | - | - | - | - | 5.77x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -1.21x | -0.82x | -1.2x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -30.12 | -32.28 | -27 | -23.88 | -19.65 | -6.34 | -5.895 | -1.22 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 6.2 |
| EBITDA | -63.57 | -71.78 | - | - | - | - | - | - |
| EBIT 1 | -70.76 | -75.91 | -67.64 | -59.75 | -57.62 | -29.6 | -43.9 | -29.9 |
| Net income 1 | -69.39 | -74.73 | -62.72 | -55.65 | -55.84 | -33.8 | -43.65 | -29 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 72.000 | 16.920 | 13.680 | 9.252 | 14.190 | 7.820 | 7.820 | 7.820 |
| Nbr of stocks (in thousands) | 2,302 | 2,315 | 2,325 | 2,334 | 3,506 | 4,577 | - | - |
| Announcement Date | 3/3/22 | 3/2/23 | 3/21/24 | 3/6/25 | 3/5/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.23x | - | - | - | 35.79M | |
| 20.25x | 7.04x | 14.2x | 1.45% | 67.98B | |
| 36.9x | 9.64x | 29.44x | 0.04% | 64.94B | |
| -77.3x | 14.92x | -71.95x | -.--% | 27.58B | |
| -15.85x | 6.12x | -7.7x | -.--% | 26.06B | |
| 29.69x | 6.35x | 16.48x | -.--% | 25.74B | |
| 27.41x | 5.13x | 17.06x | -.--% | 20.09B | |
| 49.41x | 18.23x | 36.98x | 0.31% | 17.16B | |
| 1289.22x | 37.23x | 812.54x | -.--% | 14.92B | |
| 18.23x | 5.44x | 12.69x | -.--% | 14.62B | |
| Average | 137.67x | 12.23x | 95.53x | 0.2% | 27.91B | |
| Weighted average by Cap. | 82.00x | 10.35x | 51.60x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- NXTC Stock
- Valuation NextCure, Inc.
Select your edition
All financial news and data tailored to specific country editions
